HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acupuncture and integrative oncology for taxane-induced peripheral neuropathy: a randomized multicentered study.

AbstractOBJECTIVE:
To compare the effectiveness of acupuncture alone or with additional integrative oncology modalities for taxane-induced peripheral neuropathy-related symptoms in patients with gynecological and breast cancer.
METHODS:
The study was a prospective evaluation of patients undergoing twice-weekly treatments with either acupuncture alone (single-modality, group A) or with additional manual-movement and mind-body therapies (multimodality, group B), for 6 weeks. Symptom severity was assessed at baseline, 6 weeks, and 9 weeks using the Functional Assessment of Cancer Therapy-Taxane (FACT-Tax) tool; and von Frey perception thresholds. Additional symptoms were also assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the Measure Yourself Concerns and Wellbeing (MYCaW) study tool.
RESULTS:
For the 120 participants (60 in each study arm), baseline to 6-week scores were similar in both groups for improved FACT-Tax physical wellbeing and scores for hand numbness/tingling; EORTC physical functioning and global health status; and MYCaW scores. FACT-Tax taxane subscales and scores for foot numbness/tingling improved only in group A (p=0.038), while emotional wellbeing FACT-Tax (p=0.02) and EORTC pain (p=0.005) improved only in group B. Group B showed greater improvement for FACT-Tax neuropathy-related concerns than group A at 24 hours (p=0.043) and 7 days (p=0.009) after the first treatment.
CONCLUSION:
Acupuncture alone or with additional integrative oncology modalities may help reduce neuropathy-related symptoms. The single-modality group demonstrated greater improvement for foot numbness/tingling, and the multimodality group demonstrated improvement for pain and improved emotional wellbeing and neuropathy-related concerns in the first week of treatment.
TRIAL REGISTRATION NUMBER:
NCT03290976.
AuthorsEran Ben-Arye, Dorit Gamus, Noah Samuels, Elad Schiff, David Hausner, Orit Gressel, Samuel Attias, Ofer Lavie, Adi David, Katerina Shulman, Abed Agbarya
JournalInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society (Int J Gynecol Cancer) Vol. 33 Issue 5 Pg. 792-801 (05 01 2023) ISSN: 1525-1438 [Electronic] England
PMID36600535 (Publication Type: Randomized Controlled Trial, Multicenter Study, Journal Article, Research Support, Non-U.S. Gov't)
Copyright© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Chemical References
  • taxane
  • Taxoids
Topics
  • Humans
  • Integrative Oncology
  • Quality of Life (psychology)
  • Hypesthesia
  • Acupuncture Therapy
  • Peripheral Nervous System Diseases (chemically induced)
  • Taxoids (adverse effects)
  • Pain
  • Surveys and Questionnaires

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: